Scientists target women in trial of new HIV vaccine

Hundreds of AIDS activists march through the streets of Durban during the 21st International Aids Conference on July 18, 2016. Women are the most vulnerable. PHOTO | AFP

What you need to know:

  • The study titled AMP (antibody mediated prevention)” was launched last Friday in Kisumu by Kenya Medical Research Institute (Kemri).
  • About 1,500 sexually active women aged between 18 and 40, who are at high risk, will be enrolled for the trials.

Researchers have begun a study of a vaccine that could prevent women from contracting HIV/Aids by use of a simple injection of antibodies.

Welcome!

You're all set to enjoy unlimited Prime content.